These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24704346)

  • 21. Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma.
    Vadot L; Boulin M; Guiu B; Aho LS; Vourc'h M; Musat A; Hillon P; Lepage C; Guignard MH; Fagnoni P
    J Clin Pharm Ther; 2015 Feb; 40(1):83-90. PubMed ID: 25413186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).
    Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
    J Surg Oncol; 2010 May; 101(6):476-80. PubMed ID: 20213741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety profile of sequential transcatheter chemoembolization with DC Bead™: results of 237 hepatocellular carcinoma (HCC) patients.
    Malagari K; Pomoni M; Spyridopoulos TN; Moschouris H; Kelekis A; Dourakis S; Alexopoulou E; Koskinas J; Angelopoulos M; Kornezos J; Pomoni A; Tandeles S; Marinis A; Rizos S; Kelekis D
    Cardiovasc Intervent Radiol; 2011 Aug; 34(4):774-85. PubMed ID: 21184228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis.
    Lee M; Chung JW; Lee KH; Won JY; Chun HJ; Lee HC; Kim JH; Lee IJ; Hur S; Kim HC; Kim YJ; Kim GM; Joo SM; Oh JS
    J Vasc Interv Radiol; 2017 Apr; 28(4):502-512. PubMed ID: 27856136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Lee YH; Hsu CY; Huang YH; Su CW; Lin HC; Lee RC; Chiou YY; Huo TI; Lee SD
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1581-8. PubMed ID: 22497632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multivariate analysis of prognostic factors for survival following doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Sellers MT; Huggins S; Kegley K; Pollinger HS; Shrestha R; Johnson MW; Stein LL; Panjala C; Tan M; Arepally A; Jacobs L; Caldwell C; Bosley M; Citron SJ
    J Vasc Interv Radiol; 2013 May; 24(5):647-54. PubMed ID: 23384831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma.
    Song DS; Nam SW; Bae SH; Kim JD; Jang JW; Song MJ; Lee SW; Kim HY; Lee YJ; Chun HJ; You YK; Choi JY; Yoon SK
    World J Gastroenterol; 2015 Feb; 21(8):2395-404. PubMed ID: 25741147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis.
    Pietrosi G; Miraglia R; Luca A; Vizzini GB; Fili' D; Riccardo V; D'Antoni A; Petridis I; Maruzzelli L; Biondo D; Gridelli B
    J Vasc Interv Radiol; 2009 Jul; 20(7):896-902. PubMed ID: 19497762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends and outcomes of transarterial chemoembolization in hepatocellular carcinoma: a national survey.
    Mumtaz K; Patel N; Modi RM; Patel V; Hinton A; Hanje J; Black SM; Krishna S
    Hepatobiliary Pancreat Dis Int; 2017 Dec; 16(6):624-630. PubMed ID: 29291782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.
    Garwood ER; Fidelman N; Hoch SE; Kerlan RK; Yao FY
    Liver Transpl; 2013 Feb; 19(2):164-73. PubMed ID: 23008091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies.
    Chen BB; Shih IL; Wu CH; Hsu C; Chen CH; Shih TT; Liu KL; Liang PC
    J Vasc Interv Radiol; 2014 Mar; 25(3):371-8. PubMed ID: 24468045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
    Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chemoembolization of hepatocellular carcinoma with drug eluting beads].
    Kivelä K; Seppänen J; Keski-Nisula L
    Duodecim; 2009; 125(21):2387-93. PubMed ID: 19999664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk.
    Kothary N; Weintraub JL; Susman J; Rundback JH
    J Vasc Interv Radiol; 2007 Dec; 18(12):1517-26; quiz 1527. PubMed ID: 18057286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
    Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
    J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.
    Malagari K; Pomoni M; Kelekis A; Pomoni A; Dourakis S; Spyridopoulos T; Moschouris H; Emmanouil E; Rizos S; Kelekis D
    Cardiovasc Intervent Radiol; 2010 Jun; 33(3):541-51. PubMed ID: 19937027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up.
    Ou HY; Wu YN; Yu CY; Chen CL; Hsu HW; Weng CC; Leung-Chit Tsang L; Huang TL; Tong YS; Lim WX; Cheng YF
    J Vasc Interv Radiol; 2020 Nov; 31(11):1784-1791. PubMed ID: 33023805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocellular Carcinoma Progression While on Waiting List for Liver Transplantation.
    Giacomoni A; Concone G; Di Sandro S; Lauterio A; De Carlis L
    Transplantation; 2015 Sep; 99(9):e155-6. PubMed ID: 26308419
    [No Abstract]   [Full Text] [Related]  

  • 40. Advances in endovascular therapy to treat primary hepatocellular carcinoma.
    Guo Z; Yu H; Liu C; Si T; Yang X; Zhang W; Xu Y; Li Y
    Drug Discov Ther; 2015 Oct; 9(5):342-51. PubMed ID: 26632543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.